Using dalteparin in quotidian and nocturnal hemodialysis patients: A prospective study

• Published in: Hemodialysis international Vol. 24; no. 2; pp. 195 - 201
• Main Authors: Huang, Shih‐Han S., Qi, Karen, Louzada, Martha, Lindsay, Robert M., Rehman, Faisal, Ke, Hanna, Muirhead, Norman
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.04.2020
• Subjects: dalteparin; hemodialysis; home hemodialysis; Low‐molecular weight heparin; nocturnal hemodialysis; quotidian hemodialysis; hemodialysis; quotidian hemodialysis; Low-molecular weight heparin; nocturnal hemodialysis; home hemodialysis; dalteparin
• ISSN: 1492-7535; 1542-4758
• DOI: 10.1111/hdi.12805

Introduction: Low‐molecular weight heparin, such as dalteparin, is an alternative anticoagulation method in conventional hemodialysis (HD). However, there are limited studies on its use in quotidian and nocturnal HD. We assessed the optimal dose, treatment efficacy, and patient safety of dalteparin in quotidian and nocturnal HD populations. Methods: This study included 10 quotidian (7 in‐center and 3 home) and 8 nocturnal home HD patients. Dalteparin was initiated and titrated based on clotting score in these patients. Trough anti‐Xa levels were measured. The dalteparin dose, the dialyzer and HD circuit clotting scores, and bleeding episodes were recorded at 4 weeks. Patients who continued dalteparin were followed to 12 months. Findings: For the 10 quotidian HD patients, the median dalteparin dose was 1875 units [1250, 2500] after 4 weeks. For nocturnal HD patients, five of the eight patients switched back to heparin due to high clotting scores while on dalteparin within 4 weeks. However, three patients continued on dalteparin at 4 weeks. After 12 months, one maintained on 5000 units and the other two maintained on 7500 units of dalteparin. All the clotting scores at month 12 were ≤2. One patient died due to an unrelated cause. For all patients who continued on dalteparin, only 9% of the HD treatments had circuit clotting score >2 after reaching stable dose. All trough anti‐Xa levels were <0.1 IU/mL. There were no episodes of bleeding. Fistula compression times were not increased. Discussion: This small pilot study suggests that dalteparin can be used effectively and relatively safety in quotidian HD. However, its use in nocturnal HD was only successful in a small proportion of patients. Alternative methods, including second dalteparin bolus after 4 hours of HD treatment, should be assessed for efficacy and practicality.